MRI to Measure Treatment With Antibiotics in Alzheimer's Disease (DARAD-MRI)

This study has been completed.
Sponsor:
Collaborators:
St. Peter's Hospital
St. Peter's Centre for Studies in Aging
Information provided by:
St. Joseph's Healthcare Hamilton
ClinicalTrials.gov Identifier:
NCT00692588
First received: June 4, 2008
Last updated: April 5, 2011
Last verified: April 2011
  Purpose

Objectives:

To study the changes in brain structure and function using MRI scans in patients treated for Alzheimer's disease.

Methods:

A pilot study of treating Alzheimer's disease with antibiotics showed some promise that this treatment could delay the deterioration of the mind with this disease. This study is being replicated on a larger scale, providing a more definitive answer to this question. In addition to looking at changes of the mind (through cognitive tests), we would like to use MRI scans in these patients before and after treatment to study the structural changes and the chemical changes in the brain. This would provide a non-invasive look at the bran processes that protect the brain from the effect of Alzheimer's as well as confirming that the disease has been modified with treatment.

Impact:

The novel treatment of Alzheimer's with antibiotics has provided a potential breakthrough in the field. In addition to verifying changes in the brain, MRI scans can observe HOW this process could occur, thus opening doors to other new treatments for Alzheimer's and perhaps even cures.


Condition
Alzheimer's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Magnetic Resonance Imaging to Measure Treatment Effects of Doxycycline and Rifampicin in Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by St. Joseph's Healthcare Hamilton:

Primary Outcome Measures:
  • Changes in MRI Pre Vs Post Treatment [ Time Frame: 1 Year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of Normal Controls Vs Alzheimer's Disease using MRI [ Time Frame: 1 Year ] [ Designated as safety issue: No ]

Enrollment: 58
Study Start Date: June 2008
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Placebo
Subjects who received placebo in DARAD Trial
Doxycycline
Subjects who received doxycycline in DARAD Trial
Rifampicin
Subjects who received rifampicin in DARAD Trial
Doxycycline and Rifampicin
Subjects who received doxycycline and rifampicin in DARAD Trial
Control
Normal controls

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants in the DARAD Trial (Doxycycline and Rifampicin for Alzheimer's disease).

Criteria

Inclusion Criteria:

(DARAD Trial)

  1. Male or female aged 50 years or older.
  2. Diagnosis of dementia using standardized DSM IV criteria and probable Alzheimer's disease (NINCDS-ADRDA criteria).
  3. SMMSE score 14-26 inclusive.
  4. Patients who have a consistent caregiver who will accompany them to clinic visits, ensure medication compliance, monitor and report adverse events and sign informed consent for his or her own participation.
  5. Sufficient visual, hearing and communication skills to complete standardized testing in English.
  6. Patients or their legally acceptable representatives for personal care who sign informed consent.
  7. Otherwise healthy on physical examination and screening physical and laboratory testing.

Exclusion Criteria:

(DARAD Trial)

  1. Patients with neurodegenerative diseases such as Lewy Body dementia, Parkinson's disease, Fronto-temporal Dementia, Huntington's Chorea, Down's Syndrome or Creutzfeld Jacob Disease.
  2. Cognitive impairment which may be due to any of the following conditions:

    1. acute cerebral trauma, subdural hematoma, injuries from chronic trauma like boxing.
    2. Hypoxic cerebral damage e.g. post cardiac arrest, postanesthesia etc.
    3. Vitamin deficiency like B12 deficiency will be treated and stabilized for one month before patients will be randomized to the study. Patients taking B12 for more than one month can be included in the study.
    4. Infections like cerebral abscesses, herpes, neurosyphilis, meningitis or AIDS.
    5. Primary or metastatic cerebral neoplasia.
    6. Endocrine deficiencies like hypercalcemia, hypothyroidism, hyperparathyroidism, Cushing's syndrome, severe renal failure, poorly controlled diabetes mellitus, pituitary disease, etc.
    7. Mental retardation. If a patient has one of these conditions and in the opinion of the investigator this condition has stabilized and is not contributing to the decline in cognition then this patient may be included in the study after the steering committee has reviewed the situation and approved participation.
  3. Multi-infarct dementia or significant cerebrovascular disease as evidenced by a) stroke with deficit that may confound the assessment of cognitive function or b) multiple focal signs on exam indicative of multiple ischemic events or c) findings on CT or MRI scan that show multiple lacunar infarcts, extensive periventricular white matter lesion, an infarct in the angular gyrus, the thalamus, the basal forebrain, the anterior or posterior cerebral artery territory.
  4. Patients with significant intracranial pathology such as tumour or hydrocephalus confirmed by CT or MRI in the past two years. The CT or MRI must be repeated before inclusion if the patient has experienced significant loss of consciousness or other neurological signs or symptoms, step-wise deterioration or has sustained a significant head injury since the last scan was performed. Patients with loss of consciousness, transient ischemic attacks or drop attacks, may be considered if these did not occur in the preceding twelve months.
  5. Patients with the following co-existing medical conditions:

    1. History of epilepsy or convulsions.
    2. Clinically significant psychiatric conditions (based on DSM-IV criteria) like major depression, schizophrenia. A Cornell Scale for Depression in Dementia score of 12 or more out of 38.
    3. Moderate to severe behavioural disturbances,
    4. Clinically significant hepatic, renal, pulmonary, metabolic or endocrine diseases.
    5. History of drug or alcohol abuse in the year prior to enrolment.
    6. History of myasthenia gravis.
  6. Clinically significant cardiac disease such as:

    1. Cardiac surgery in the past six months.
    2. Unstable angina or poorly controlled congestive heart failure (NYHA III or IV).
    3. Uncontrolled hypertension with systolic pressure greater that 180 mmHg. or diastolic pressure greater that 110 mmHg.
  7. Patients taking anti-dementia treatments with the following exceptions: donepezil, galantamine, rivastigmine, memantine, ASA up to 650 mg OD, Vitamin E 400 i.u., multi B vitamins, Ginko biloba, Cox II inhibitors or statins. In all cases the dose should have been stable for three months or more, and not be expected to change for the duration of the trial.
  8. Patients enrolled in other clinical trials with investigational drugs.
  9. Patients taking long term antibiotics (more than one month in the past six months).
  10. Allergies to these antibiotics.

(MRI)

  1. Cardiac pacemaker or implantable defibrillator
  2. Cerebral aneurysm clip
  3. Neural stimulator (e.g. TENS-Unit)
  4. Any type of ear implant
  5. Ocular foreign body (e.g. metal shavings)
  6. Any implanted device (e.g. insulin pump, drug infusion device)
  7. Metal shrapnel or bullet.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00692588

Locations
Canada, Ontario
St. Joseph's Healthcare
Hamilton, Ontario, Canada, L8N 4A6
Sponsors and Collaborators
St. Joseph's Healthcare Hamilton
St. Peter's Hospital
St. Peter's Centre for Studies in Aging
Investigators
Principal Investigator: Mohammed A Warsi, (Hon)BSc, MSc, MD, FRCP(C) McMaster University
Study Director: Michael D Noseworthy, (Hon)BSc, MSc, PhD St. Joseph's Hospital
Study Director: William Molloy, MBBch, MRCP, FRCP(C) St. Peters Hospital
  More Information

No publications provided

Responsible Party: Dr. Mohammed Ali Warsi, McMaster University
ClinicalTrials.gov Identifier: NCT00692588     History of Changes
Other Study ID Numbers: R.P. #07-2949
Study First Received: June 4, 2008
Last Updated: April 5, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by St. Joseph's Healthcare Hamilton:
Alzheimer's Disease
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Diffusion Tensor Imaging
Susceptibility Weighted Imaging
Doxycycline
Rifampicin

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Doxycycline
Rifampin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on August 21, 2014